Search for a command to run...
Emcure Pharmaceuticals Ltd. demonstrates solid profitability metrics but lacks growth momentum compared to its peers. It stands out for its low debt levels and reasonable valuation, making it a potential value pick despite its stagnated growth. Other companies with strong growth and profitability metrics like Cipla and Dr. Reddy's lead the sector.
Stocks | CMP | Market Cap | P/E | ROCE (%) | Debt/Equity |
---|---|---|---|---|---|
EMCURE | ₹1,378.70 | ₹26,127.52Cr | 82.39 | 22.49% | 0.16 |
SUNPHARMA | ₹1,563.35 | ₹3,75,099.26Cr | 87.59 | 17.60% | 0.04 |
DIVISLAB | ₹6,091.05 | ₹1,61,698.50Cr | 73.20 | 16.46% | - |
CIPLA | ₹1,587.60 | ₹1,28,217.27Cr | 23.73 | 22.77% | 0.01 |
TORNTPHARM | ₹3,581.55 | ₹1,21,215.77Cr | 61.53 | 24.28% | 0.57 |
DRREDDY | ₹1,280.30 | ₹1,06,835.27Cr | 15.50 | 26.86% | 0.07 |
MANKIND | ₹2,518.95 | ₹1,03,926.59Cr | 55.18 | 28.38% | 0.02 |